-$0.35 Earnings Per Share Expected for ADMA Biologics Inc (ADMA) This Quarter

Analysts expect ADMA Biologics Inc (NASDAQ:ADMA) to announce earnings per share (EPS) of ($0.35) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for ADMA Biologics’ earnings. The lowest EPS estimate is ($0.39) and the highest is ($0.31). ADMA Biologics reported earnings of ($0.55) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 36.4%. The business is scheduled to issue its next quarterly earnings report on Friday, August 10th.

According to Zacks, analysts expect that ADMA Biologics will report full-year earnings of ($1.35) per share for the current year, with EPS estimates ranging from ($1.50) to ($1.24). For the next fiscal year, analysts forecast that the company will report earnings of ($0.23) per share, with EPS estimates ranging from ($0.36) to $0.00. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover ADMA Biologics.

A number of equities research analysts have recently issued reports on ADMA shares. LADENBURG THALM/SH SH lowered their price target on shares of ADMA Biologics to $7.50 and set a “buy” rating on the stock in a report on Wednesday. ValuEngine raised shares of ADMA Biologics from a “strong sell” rating to a “sell” rating in a report on Saturday, April 7th. Finally, Maxim Group set a $10.00 price target on shares of ADMA Biologics and gave the stock a “buy” rating in a report on Tuesday, April 24th.

Shares of ADMA Biologics traded up $0.08, reaching $4.87, on Friday, MarketBeat Ratings reports. The stock had a trading volume of 15,714 shares, compared to its average volume of 141,609. ADMA Biologics has a 1 year low of $2.01 and a 1 year high of $5.70. The company has a market cap of $210.27 million, a price-to-earnings ratio of -2.55 and a beta of 2.11. The company has a current ratio of 4.92, a quick ratio of 3.60 and a debt-to-equity ratio of 1.76.

In related news, CEO Adam S. Grossman acquired 52,301 shares of the firm’s stock in a transaction that occurred on Friday, June 8th. The shares were bought at an average cost of $4.78 per share, for a total transaction of $249,998.78. Following the completion of the transaction, the chief executive officer now owns 32,527 shares in the company, valued at $155,479.06. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jerrold B. Grossman acquired 20,921 shares of the firm’s stock in a transaction that occurred on Friday, June 8th. The stock was bought at an average price of $4.78 per share, for a total transaction of $100,002.38. Following the completion of the transaction, the director now owns 98,007 shares of the company’s stock, valued at approximately $468,473.46. The disclosure for this purchase can be found here. Over the last three months, insiders bought 78,222 shares of company stock worth $373,901. Insiders own 16.90% of the company’s stock.

Several hedge funds have recently bought and sold shares of ADMA. Perceptive Advisors LLC increased its position in shares of ADMA Biologics by 429.9% in the fourth quarter. Perceptive Advisors LLC now owns 3,821,102 shares of the biotechnology company’s stock worth $12,266,000 after purchasing an additional 3,100,000 shares during the last quarter. Consonance Capital Management LP increased its position in shares of ADMA Biologics by 164.3% in the fourth quarter. Consonance Capital Management LP now owns 3,367,635 shares of the biotechnology company’s stock worth $10,810,000 after purchasing an additional 2,093,702 shares during the last quarter. Broadfin Capital LLC bought a new position in shares of ADMA Biologics in the fourth quarter worth approximately $3,538,000. 683 Capital Management LLC bought a new position in shares of ADMA Biologics in the fourth quarter worth approximately $3,050,000. Finally, Morgens Waterfall Vintiadis & Co. Inc. bought a new position in shares of ADMA Biologics in the fourth quarter worth approximately $1,605,000. Institutional investors own 37.42% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply